trial

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

NCTId NCT00216281
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 126 (actual)
Sponsored by Indiana University
Primary completion 2006-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
126 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-09
Primary completion
2006-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
—

Sponsors

Indiana UniversityLead Sponsor
Hoffmann-La RocheCollaborator
Shekhar, Anantha M.D., Ph.D.Collaborator

Investigators

1
Anantha Shekhar, MD, PhDPrincipal Investigator

Sites

1 total
Indianapolis, United States

Linked catalysts

1
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine — primary completion2006-10

Facts & assertions

4 sourced
Enrollment
126
Phase
PHASE3
Primary Completion Date
2006-10
Status
TERMINATED
relationships
The graph out of here
lead_sponsor
Indiana University
company
collaborator
Hoffmann-La Roche
company
Shekhar, Anantha M.D., Ph.D.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Anantha Shekhar, MD, PhD
person